Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1411 • ACR Convergence 2023
Prevalence of Early Axial Spondyloarthritis in the Be-GIANT Cohort Based on the ASAS Consensus Definition of Early Axial Spondyloarthritis
Gaelle Varkas¹, Ann-Sophie De Craemer², Zuzanna Lukasik¹, Thomas Renson³, Liselotte Deroo⁴, Philippe Carron⁵, Dirk Elewaut⁶ and Filip Van den Bosch⁷, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Dept. of Pediatrics, Ghent University Hospital, Ghent, Belgium, ⁴Ghent University, Gent, Belgium, ⁵UZ Gent, Gent, Belgium, ⁶Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁷Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Recently, the Assessment of SpondyloArthritis international Society (ASAS) community, led by the ASAS-SPEAR (SPondyloarthritis EARly definition) working group, endorsed a uniform definition for early…
Abstract Number: 2439 • ACR Convergence 2023
Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
Fataneh Tavasolian¹, starlee lively², Chiara Pastrello³, Michael Tang², Melissa Lim², Addison Pacheco², Zoya Qaiyum², Enoch Yau², Zeynep Baskurt⁴, Igor Jurisica⁵, Mohit Kapoor⁶ and Robert Inman², ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ⁴Department of Biostatistics, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁶Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Recent advances in understanding the biology of Ankylosing Spondylitis (AS) using innovative genomic and proteomic approaches offer the opportunity to address current challenges in…
Abstract Number: 0327 • ACR Convergence 2023
Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre
Saadia Sasha Ali¹, Karafotias Ioasaf², Bechman Katie³, Andrew Rutherford⁴, Sophia Steer³ and Elena Nikiphorou³, ¹King's College Hospital, Epsom, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, United Kingdom, ⁴King's College Hospital, London, United Kingdom
Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…
Abstract Number: 0537 • ACR Convergence 2023
Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation
Natalia Rivera¹, elena abad plou², Eva Galindez-Agirregoikoa³, Eduardo Cuende⁴, Ana Rosa Intxaurbe⁵, Juan M Blanco Madrigal³, Lucia Vega-Alvarez³, Carmen Lucia Garcia-Gomez⁶, Maria Enjuanes-Noguero⁷, Olaia Fernandez-Berrizbeitia⁸, Maria Rosa Exposito Molinero⁹, Maria Esther Ruiz Lucea³, Ignacio Torre Salaberri⁵, iñigo Gorostiza Hormaeche³ and Maria Luz Garcia Vivar³, ¹Biocruces Bizkaia Health Research Institute, Research area, Bilbao, Spain, ²Hospital universitario de Basurto, Bilbo, Spain, ³Basurto University Hospital, Bilbao, Spain, ⁴Basurto University Hospital, Rheumatology, Madrid, Spain, ⁵Basurto University Hospital, Rheumatology, Bilbao, Spain, ⁶Basurto University Hospital, Rheumatology, Terrassa, Spain, ⁷Hospital Universitario de Basurto, Bilbao, Spain, ⁸Spanish Health Care Service, Bilbao, Spain, ⁹Hospital de Basurto, Bilbao, Spain
Background/Purpose: Before COVID pandemic, telehealth use for the followup of rheumatic disease patients had been limited, but nowadays it appears as a more sustainable model…
Abstract Number: 1392 • ACR Convergence 2023
Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project
Denis Poddubnyy¹, Marc Kämmerer², Marcus Kremers³, Berit Schoppen³, Charlotte Arens³, Annette Wiedon⁴, Imke Redeker⁵ and Xenofon Baraliakos⁶, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²VISUS Health IT GmbH, Bochum, Germany, ³MedEcon Telemedizin GmbH / MedEcon Ruhr GmbH, Bochum, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Ruhr Universität Bochum, Bochum, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is often diagnosed late, while there is also a problem of over- and misdiagnosis in patients with chronic back pain. Imaging,…
Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Melissa Lim¹, Shaghayegh Foroozan², Zoya Qaiyum³, Michael Tang¹, Enoch Yau⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University Health Network/University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
Abstract Number: 2442 • ACR Convergence 2023
Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis
Hillary Struthers¹, Emily Vance¹, Kofi Asare-Konadu¹, Holly Rosenzweig² and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Healthcare System, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…
Abstract Number: 0333 • ACR Convergence 2023
Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Heather Lapidus Glassner and Elizabeth Luce, MyHealthTeam, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) leads to symptoms of pain, stiffness, swelling, and fatigue. Patients often report periods of increased symptoms (flares) followed by remission.The purpose…
Abstract Number: 0539 • ACR Convergence 2023
Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis
Maxime Dougados¹, David Bulbin², Heather Jones³, Tianming Gao⁴, Anna Shmagel⁵, Thomas Poznanski⁶, Abhijeet Danve⁷ and Karl Gaffney⁸, ¹Université de Paris, Paris, France, ²Geisinger Health System, Danville, PA, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Plainfield, IL, ⁷Yale University, New Haven, CT, ⁸Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom
Background/Purpose: Axial SpA (axSpA) and FM manifest with overlapping clinical features such as pain, fatigue, and stiffness, yet their treatment is distinctly different. FM is…
Abstract Number: 1394 • ACR Convergence 2023
Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study
Bon San Koo¹, Subin Hwang¹, Ye-Jee Kim², Soo Min Ahn² and Wook Jang Seo³, ¹Inje University Seoul Paik Hospital, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea
Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
Abstract Number: 1783 • ACR Convergence 2023
Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis
Marcos Chiñas¹, Daniela Fernandez-Salinas¹, Vitor Aguiar¹, Victor Caballero-Nieto², Micah Lefton³, Joerg Ermann⁴ and Maria Gutierrez-Arcelus¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Montpellier, France, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not…
Abstract Number: 2545 • ACR Convergence 2023
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study
Atul Deodhar¹, Jerzy Supronik², Alan Kivitz³, Guillermo Valenzuela⁴, Karen Kapur⁵, Susanne Rohrer⁶, Eva Dokoupilova⁷, Hanno Richards⁶ and Karel Pavelka⁸, ¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ²OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: While subcutaneous secukinumab (SEC) is approved for the treatment of axial spondyloarthritis (axSpA), some patients may benefit more from intravenous (IV) administration. This study…
Abstract Number: 0500 • ACR Convergence 2023
Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Jose Federico Diaz-Gonzalez¹, Luis Cea-Calvo², Enrique González-Dávila³, Marta Sánchez-Jareño², Manuel Enrique Pombo Suarez⁴, Fernando Alonso⁵ and Isabel Castrejon⁶, ¹Hospital Universitario de Canarias, La Laguna, Spain, ²Medical Affairs, MSD Spain, Madrid, Spain, ³Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ⁵Spanish Society of Rheumatology, Madrid, Spain, ⁶Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Selecting patients with the highest probability of long-term retention of biological treatments is important from a clinical and cost-effectiveness point of view. In this…
Abstract Number: 0540 • ACR Convergence 2023
The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study
Angela Crowley¹, Lori Siegel¹, Pendleton Wickersham², Heather Jones³, Dan Webster⁴, Anna Shmagel⁵, Ana Biljan⁶, Uta Kiltz⁷ and Philip Helliwell⁸, ¹Illinois Bone and Joint Institute, Gurnee and Hinsdale, IL, ²Methodist Hospital, Baptist Medical Center and CHRISTUS Santa Rosa Hospital - Westover Hills, San Antonio, TX, ³AbbVie, Inc., Mettawa, IL, ⁴AbbVie, Inc., Libertyville, IL, ⁵AbbVie, Inc., Long Grove, IL, ⁶AbbVie, Inc., Buffalo Grove, IL, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with AS, higher BMI has been linked to higher disease activity1. However, given that BMI can be a poor indicator of…
Abstract Number: 1395 • ACR Convergence 2023
Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis
Elisabet Lindqvist¹, Johan Karlsson Wallman¹, Jonas Sagard², Tor Olofsson¹ and Elisabeth Mogard¹, ¹Lund University and Skåne University Hospital, Lund, Sweden, ²Skåne University Hospital, Lund, Sweden
Background/Purpose: Physical activity is part of the treatment of axial spondyloarthritis (axSpA), but despite this almost half of the patients do not meet the required…

« Previous Page
1
…
8
9
10
11
12
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].